Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LARS1 | Q9P2J5 | 3/20 | 0.59 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.42 |
| ▸ | CTSB | P07858 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | KAT6A | Q92794 | 4/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3101143 | 0.89 | LARS1 (0.53) | LARS1CAPN1CTSBBCL2L1MCL1 | |
| SCHEMBL3092667 | 0.87 | LARS1 (0.47) | LARS1CTSBBCL2L1MCL1 | |
| SCHEMBL3092864 | 0.87 | LARS1 (0.48) | LARS1F2NLRP3KAT6AHTR2A | |
| SCHEMBL3102827 | 0.86 | MEN1 (0.50) | LARS1F2NLRP3KAT6AHTR2A | |
| SCHEMBL3101068 | 0.85 | LARS1 (0.46) | LARS1F2NLRP3KAT6AHTR2A | |
| SCHEMBL3096954 | 0.84 | LARS1 (0.45) | LARS1F2NLRP3KAT6AMEN1 | |
| SCHEMBL3087740 | 0.83 | LARS1 (0.44) | LARS1F2NLRP3KAT6AMEN1 | |
| SCHEMBL3085443 | 0.82 | PPARG (0.49) | LARS1F2KAT6AHTR2AHTR2C | |
| SCHEMBL3080156 | 0.81 | USP30 (0.49) | LARS1F2KAT6AMEN1KMT2A | |
| SCHEMBL3092646 | 0.81 | KAT6A (0.46) | LARS1CTSBF2NLRP3KAT6A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180280326-A1 | MEDICAMENT FOR PREVENTING OR INHIBITING ACUTE KIDNEY INJURY | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2018-10-04 | — | — | US | claimed |
| US-10071099-B2 | Medicament for suppressing malignant tumor metastasis | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2018-09-11 | — | — | US | claimed |
| EP-3127554-A1 | MEDICINE FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | National Cerebral and Cardiovascular Center (JP) | 2017-02-08 | — | — | EP | claimed |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2017-01-19 | — | — | US | claimed |
| EP-2172450-B9 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-08 | — | — | EP | claimed |
| EP-2172450-B1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-10-16 | — | — | EP | claimed |
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | claimed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | claimed |
| EP-2172450-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-04-07 | — | — | EP | claimed |
| US-20180280326-A1 | MEDICAMENT FOR PREVENTING OR INHIBITING ACUTE KIDNEY INJURY | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2018-10-04 | — | — | US | disclosed |
| US-10071099-B2 | Medicament for suppressing malignant tumor metastasis | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2018-09-11 | — | — | US | disclosed |
| EP-3127554-A1 | MEDICINE FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | National Cerebral and Cardiovascular Center (JP) | 2017-02-08 | — | — | EP | disclosed |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2017-01-19 | — | — | US | disclosed |
| EP-2172450-B9 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-08 | — | — | EP | disclosed |
| EP-2172450-B1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| EP-2172450-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280326-A1 | MEDICAMENT FOR PREVENTING OR INHIBITING ACUTE KIDNEY INJURY | AGTR2, AGTR1, REN | LARS1 4702/4885CAPN1 2480/4885CTSB 1255/4885 |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | LARS1 1976/4885CAPN1 3775/4885CTSB 2516/4885 |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | AGTR2, MME, AGTR1 | LARS1 4053/4885CAPN1 2296/4885CTSB 1308/4885 |
| US-10071099-B2 | Medicament for suppressing malignant tumor metastasis | AGTR2, MME, AGTR1 | LARS1 4053/4885CAPN1 2296/4885CTSB 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.